FDA Drug Recalls

Recalls / Class II

Class IID-1274-2019

Product

Ketorolac Tromethamine Injection, USP, 60 mg per 2 mL (30 mg per mL), 2 mL Vials, Rx only, Mfd. for Sagent Pharmaceuticals, Schaumburg, IL 60195, NDC: 25021-701-02

Brand name
Ketorolac Tromethamine
Generic name
Ketorolac Tromethamine
Active ingredient
Ketorolac Tromethamine
Route
Intramuscular, Intravenous
NDCs
25021-700, 25021-701
FDA application
ANDA204216
Affected lot / code info
Lot #: M813513, Exp. Feb 2020

Why it was recalled

Lack of Sterility Assurance: Microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.

Recalling firm

Firm
Sagent Pharmaceuticals Inc
Manufacturer
Sagent Pharmaceuticals
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
1901 N Roselle Rd Ste 700, N/A, Schaumburg, Illinois 60195-3194

Distribution

Quantity
75,825 vials
Distribution pattern
Nationwide USA and Puerto Rico

Timeline

Recall initiated
2019-04-30
FDA classified
2019-05-09
Posted by FDA
2019-05-15
Terminated
2020-09-28
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1274-2019. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Ketorolac Tromethamine · FDA Drug Recalls